RxDoctor Payments Data

Keisha Allen, PA

Physician Assistant · McDowell, KYNPI 1871843573

Payments from drug & device makers

$1,103in general payments, 2019–2025

Across 64 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$156
  • AstraZeneca$126
  • Lilly USA, LLC$123
  • Novo Nordisk$114
  • Pfizer$91
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$91
  • plus $402 from 12 others

What the payments were for

  • Food & beverage$1,103100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,103 in reported general payments places this provider in the 70th percentile of 1,448 physician assistant providers in Kentucky.

See all physician assistant providers in Kentucky

Medicare billing

Part B allowed, 2024
$13,937
Medicare patients
78
Services billed
233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide265$274,540
FarxigaDapagliflozin Propanediol184$108,718
OzempicSemaglutide102$95,334
JardianceEmpagliflozin125$74,980
Breztri AerosphereBudesonide/Glycopyr/Formoterol78$60,292
EliquisApixaban63$48,783
RybelsusSemaglutide39$45,043
ZenpepLipase/Protease/Amylase12$34,323
LinzessLinaclotide57$32,192
TradjentaLinagliptin48$24,648
XareltoRivaroxaban34$21,187
EntrestoSacubitril/Valsartan19$17,270
Tresiba Flextouch U-200Insulin Degludec20$16,780
TrulicityDulaglutide17$16,688
JanuviaSitagliptin Phosphate21$16,609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$123$291,228282 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$126$178,091292 claims
Novo NordiskOzempic, Rybelsus$114$140,376141 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Combivent Respimat$43$116,196203 claims
PfizerEliquis$91$48,78363 claims
AbbVieLinzess$56$32,19257 claims
NovartisEntresto$156$17,27019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,448 physician assistant providers in Kentucky.

Other physician assistant in McDowell

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →